Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Exact Sciences Jumped Higher Today

By Brian Orelli, PhD - Jan 22, 2020 at 12:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Potential competitors for its colon cancer test Cologuard aren't ready for prime time.

What happened

Shares of Exact Sciences (EXAS -1.54%) are up 9.2% at 11:49 a.m. EST, having been up as much as 12% today, following the release of abstracts for the 2020 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO-GI) Symposium yesterday evening.

So what

Exact Sciences didn't seem to have any major presentations on its Cologuard colon cancer test at the meeting, but the healthcare company's potential private-company competitors did. And to Exact Sciences' benefit, they seem to fall short of being ready to compete with Cologuard.

Grail's Circulating Cell-free Genome Atlas study, which tests for tumor DNA in patients' blood, found 82% of all colon cancers, including 96% of stage 4 tumors, but only 72% of tumors in earlier stages 1-3.

Freenome's blood-based screening test was able to detect 80% of early-stage colon cancers and 83% of late-stage tumors.

Investors should watch for more details in the presentations at the ASCO-GI symposium, which starts tomorrow, but so far Grail's and Freenome's tests seem to be falling short of Cologuard, which found 92% of all colon cancers in its pivotal clinical trial.

Doctor talking to a patient in an exam room

Image source: Getty Images.

Now what

Given the choice, many patients would rather have a blood test than use Cologuard, which requires collecting a fecal sample. But as long as the blood tests aren't as sensitive, doctors will continue to prescribe Cologuard, which is still much more pleasant than a colonoscopy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$53.17 (-1.54%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.